Business Wire

ADVA and PSNC showcase 1200G channel transmission at SC19

19.11.2019 17:45:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that it’s hosting a joint showcase with PSNC at SC19 that features the industry’s first 1200Gbit/s optical channel transmission. Built upon the ADVA FSP 3000 TeraFlex™ terminal, the demo underscores the power of adaptive technology to maximize bandwidth efficiency in any network scenario. Using fractional QAM capabilities to boost fiber utilization and channel capacity, the demo highlights how network operators and enterprises can cost-effectively inject capacity into their networks without major upgrades. At SC19, TeraFlex™ will carry 1200Gbit/s channels in a 150GHz window or 800Gbit/s channels in a 100GHz window, delivering an industry-leading spectral efficiency of 8bit/s/Hz. These figures set a new benchmark for a commercially available product. The ADVA FSP 3000 TeraFlex™ has now been shipping for several months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005670/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The FSP 3000 TeraFlex™ helps customers inject capacity into their networks without major upgrades (Photo: Business Wire)

“As we approach the Shannon Limit, our compact and open FSP 3000 TeraFlex™ provides an entirely new route to network capacity expansion. This demo reveals how operators can enhance optical paths and reduce cost per bit right now,” said Christoph Glingener, CTO, ADVA. “Transmission terminal design is all about utilizing fiber in the most efficient way, and that’s why our FSP 3000 TeraFlex™ is the high-speed terminal of choice. By providing a 1200Gbit/s channel that consumes only 150GHz of spectrum, we’re leading the industry with spectral efficiency and channel capacity. Compared with the promise of rival 800Gbit/s solutions that are still many months away, we’re delivering 50% more capacity today – and with the added bonus of significantly better reach.”

Presented at SC19, the live demo highlights how spectral efficiency is key to maximizing bandwidth in existing networks. It shows how super-channels in increments of 50GHz are ideal for maximizing client port flexibility while ensuring compatibility with legacy line systems. Using software-defined fractional QAM modulation and adaptive baud rate capabilities, the ADVA FSP 3000 TeraFlex™ can support 1200Gbit/s channels carrying three 400Gbit/s clients or 800Gbit/s channels carrying two 400Gbit/s clients. The reach and spectral efficiency of the dual-core coherent engine implementation is superior to future single-core 800Gbit/s concepts that have reduced client port flexibility and often leave spectrum unutilized.

“Terabit channels are fast becoming essential. Our network enables Europe’s scientific community to share huge data sets and access the most advanced supercomputing applications. But empowering those researchers to stay at the forefront of discovery requires a new level of reach and spectral efficiency. With this demo, we’re showing how mission-critical long-haul networks like ours, which are not fiber-rich, can meet unprecedented data demand,” commented Artur Binczewski, director, Network Division, PSNC. “The ADVA FSP 3000 TeraFlex™ provides the flexibility and granularity needed to squeeze maximum value from our fiber plant. Now we can transmit twelve 100Gbit/s or three 400Gbit/s signals in a single Terabit channel that consumes just 150GHz of spectrum. That level of efficiency enables us to achieve more than we ever thought possible with our DCI network.”

The demo will be on display at SC19 at booth 1955 until Thursday, November 21.

Further details of the demo are available in these slides: https://adva.li/sc19-slides.


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About PSNC
Poznan Supercomputing and Networking Center (PSNC) affiliated to the Institute of Bioorganic Chemistry of the Polish Academy of Sciences is an internationally known node of the European Research Area in the field of IT infrastructure of science and an important R&D center in the field of information and communication technologies (ICT). As a development center of e-Infrastructure, PSNC designed and built the Metropolitan Network POZMAN, High Performance Computing Center and the national broadband network PIONIER, maintained and still developed by PSNC. We are an institution of high development potential. A positive consequence of the Centre's exemplary activity in acquiring and implementing projects was the establishment of broad cooperation with international institutions. Projects developed at PSNC include cooperation with 927 units from 59 countries. All projects are focused on IT technology and concern new generation networks, grids, portals, digital libraries, IT energy efficiency, climate, weather, air quality, new sources of energy, digital humanities, personalized medicine, intelligent agriculture, industry 4.0, astronomy, bioinformatics, Big Data analysis, artificial intelligence, New Media, education, Smart City, cyber security. The list of areas of activity in which PSNC undertakes work is constantly expanding, providing an important example of taking up new technological challenges. www.man.poznan.pl/online/en

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye